Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
MatthewsDRDejagerSAhrenBFonsecaVFerranniniECouturierAet al
Key Milestones Timeline Eli Lillys Strategic Context Retatrutides development occurs within Eli Lillys broader metabolic disease portfolio, which also includes tirzepatide (approved as Mounjaro for type 2 diabetes and Zepbound for obesity) and orforglipron (an oral GLP-1R agonist in Phase 3 development)
It also has significant anti-inflammatory properties and supports gut mucosal integrity
The R group side chains may be nonpolar, polar uncharged, or charged, depending on the functional group, pH, and the pKa of any ionizable side-chain group
Any deviation suggests contamination or degradation
Increase exercise intensity and volume if your body is ready
